International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2012 cancer fact sheets [homepage on the Internet]. Lyon CEDEX: IARA; 2012 [cited 2014 Jul 14]. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

Lester SC. The breast. In: Kumar V, Abbas AK, Aster JC, editors. Robbin and Cotran pathologic basis of disease. 9th ed. Philadelphia: Elsevier Saunders; 2014;p.1043-71.

Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R, et al. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press;2003;p.13-23.

National Cancer Institute at the National Institutes of Health. Breast Cancer Treatment (PDQ®): treatment options for ductal carcinoma in situ [homepage on the Internet]. Bethesda: NCI; 2014 [cited 2014 Jul 20]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page6

National Cancer Institute at the National Institutes of Health. Breast Cancer Treatment (PDQ®): treatment options by stage [homepage on the Internet]. Bethesda: NCI; 2014 [cited 2014 Jul 20]. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/breast/Patient/page8

Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28:1076–91.

Hicks DG. Immunohistochemistry in the diagnostic evaluation of breast lesions. Appl Immunohistochem Mol Morphol 2011;19:501–5.

Mukai K, Iwaya K. CD10 expression in normal breast and breast cancer tissues. In: Hayat MA, editor. Handbook of immunohistochemistry and in situ hybridization of human varcinomas; molecular genetics; lung and breast carcinomas. Burlington: Elsevier; 2004;p.299-305.

Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397–405.

Kalof AN, Tam D, Beatty B, Cooper K. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 2004;57:625–9.

Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. P-cadherin expression in breast cancer: a review. Breast Cancer Res 2007;9:214.

Albergaria A, Ribeiro AS, Vieira AF. P-cadherin role in normal breast development and cancer. Int J Dev Biol 2011;55:811–22.

Han AC. Role of cadherins in breast cancer. In: Hayat MA, editor. Handbook of immunohistochemistry and in situ hybridization of human carcinomas, volume 1 molecular genetics; lung and breast carcinomas. Burlington: Elsevier; 2004;p.343-9

Peralta SA, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86:1263–72.

Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch 2002;440:16–21.

Liu N, Yu Q, Liu TJ, Gebreamlak EP, Wang SL, Zhang RJ, et al. P-cadherin expression and basal-like subtype in breast cancers. Med Oncol 2012;29:2606–12.

Gamallo C, Moreno-Bueno G, Sarrió D, Calero F, Hardisson D, Palacios J. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol 2001;14:650–4.

Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, et al. P-cadherin expression as a prognostic biomarker in a 3,992 case tissue microarray series of breast cancer. Mod Pathol 2011;24:64–81.

Kovacs A, Walker R. P-cadherin as a marker in the differential diagnosis of breast lesions. J Clin Pathol 2003;56:139–41.

Bhatia Y. P-cadherin as myoepithelial cell marker for differential diagnosis of benign and malignant breast lesions. Indian J Pathol Microbiol 2013;56:6–9.

Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A. Anomalous expression of P-Cadherin in breast carcinoma correlation with E-cadherin expression and pathological features. Am J Surg Pathol 1995;146:605–12.